111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
银杏叶提取物（EGb 761）标准化制剂治疗膝骨关节炎：综述性文章
Authors Wang Y , Liu Z , Liu Y , Chu H
Received 30 June 2025
Accepted for publication 5 December 2025
Published 16 December 2025 Volume 2025:19 Pages 11217—11225
DOI https://doi.org/10.2147/DDDT.S550540
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Tamer Ibrahim
Yunqing Wang,1,2 Ziyu Liu,1,2 Yong Liu,1 Hongshang Chu1,3
1Department of Traumatic Orthopedics, Affiliated Hospital of Shandong Second Medical University, Weifang, 261031, People’s Republic of China; 2School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, People’s Republic of China; 3Clinical Research Center, Affiliated Hospital of Shandong Second Medical University, Weifang, 261042, People’s Republic of China
Correspondence: Hongshang Chu, Email wyfychuhs@sdsmu.edu.cn Yong Liu, Email liuyong7312@outlook.com
Abstract: Knee osteoarthritis (KOA), a prevalent degenerative joint disorder characterized by progressive cartilage degradation, synovial inflammation, and joint dysfunction, remains a major cause of disability worldwide with limited therapeutic options. Ginkgo biloba extract (EGb 761), a standardized multi-component natural product containing flavonoid glycosides and terpene lactones, has demonstrated anti-inflammatory, antioxidant, anti-apoptotic, and Chondroprotection. This narrative review synthesizes current experimental and clinical findings on the potential therapeutic role of EGb 761 in KOA. To provide a comprehensive overview, relevant literature published up to 2025 was identified through searches in PubMed, Scopus, and Web of Science, as well as by screening reference lists of key studies. Considering the complex pathogenesis of KOA and the multi-target pharmacological actions of EGb 761, this review aims to consolidate existing findings and clarify its potential role as an adjunctive therapy. Preclinical and clinical studies suggest that EGb 761 may reduce inflammation, oxidative stress, and chondrocyte apoptosis, leading to modest improvements in pain relief and joint function, while demonstrating a favorable safety profile. However, current evidence is limited by small sample sizes, methodological heterogeneity, short study durations, and risk of bias. While the available evidence is promising, it remains inconclusive that EGb 761 offers significant therapeutic benefits for individuals with KOA. Further high-quality randomized controlled trials are warranted.
Keywords: ginkgo biloba extract, EGb 761, knee osteoarthritis, KOA, efficacy and therapeutic effect
1Department of Traumatic Orthopedics, Affiliated Hospital of Shandong Second Medical University, Weifang, 261031, People’s Republic of China; 2School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, People’s Republic of China; 3Clinical Research Center, Affiliated Hospital of Shandong Second Medical University, Weifang, 261042, People’s Republic of China
Correspondence: Hongshang Chu, Email wyfychuhs@sdsmu.edu.cn Yong Liu, Email liuyong7312@outlook.com
Abstract: Knee osteoarthritis (KOA), a prevalent degenerative joint disorder characterized by progressive cartilage degradation, synovial inflammation, and joint dysfunction, remains a major cause of disability worldwide with limited therapeutic options. Ginkgo biloba extract (EGb 761), a standardized multi-component natural product containing flavonoid glycosides and terpene lactones, has demonstrated anti-inflammatory, antioxidant, anti-apoptotic, and Chondroprotection. This narrative review synthesizes current experimental and clinical findings on the potential therapeutic role of EGb 761 in KOA. To provide a comprehensive overview, relevant literature published up to 2025 was identified through searches in PubMed, Scopus, and Web of Science, as well as by screening reference lists of key studies. Considering the complex pathogenesis of KOA and the multi-target pharmacological actions of EGb 761, this review aims to consolidate existing findings and clarify its potential role as an adjunctive therapy. Preclinical and clinical studies suggest that EGb 761 may reduce inflammation, oxidative stress, and chondrocyte apoptosis, leading to modest improvements in pain relief and joint function, while demonstrating a favorable safety profile. However, current evidence is limited by small sample sizes, methodological heterogeneity, short study durations, and risk of bias. While the available evidence is promising, it remains inconclusive that EGb 761 offers significant therapeutic benefits for individuals with KOA. Further high-quality randomized controlled trials are warranted.
Keywords: ginkgo biloba extract, EGb 761, knee osteoarthritis, KOA, efficacy and therapeutic effect